ClinicalTrials.gg
Sign In
CompletedNCT05727137Updated Apr 12, 2024

Daily Single Shot Adductor Canal Block Versus Continuous Adductor Canal Block After Total Knee Arthroplasty

An interventional study of Single shot adductor canal block and Continuous adductor canal block in Postoperative Pain, sponsored by Seoul National University Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

This study will compare the analgesic efficacy of daily single-shot adductor canal block(ABC) versus continuous ACB after total knee arthroplasty (TKA).

Read the detailed description

Patients 19-75 years old, of ASA classification I-III scheduled for unilateral TKA, will be enrolled and randomized into two groups, single-shot ACB group and continuous ACB group. In both groups, participants will be administered a single-shot ACB immediately after the end of the operation. The single-shot ACB group will receive two separate single-shot ACBs, on the first and second postoperative day. A nerve block catheter will be placed in patients in the continuous ACB group, which will be connected to a patient-controlled analgesia pump until the second postoperative day. The primary outcome of this study is the average NRS pain score at rest from the end of surgery to 2 days after surgery.

02

Conditions studied

  • Postoperative Pain

Browse trials for

03

In context

Pain, Postoperative

5,224 studies on the registry are indexed under Pain, Postoperative; 1,154 are open to participants now.

This study's enrollment of 80 is close to the median of 75 across 4,457 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,897 studies on the registry; 273 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Browse Seoul National University Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA classification I, II, III
  • Patients scheduled for unilateral knee arthroplasty

Exclusion criteria

Exclusion Criteria:

  • Anesthesia other than spinal anesthesia
  • Chronic opioid use
  • Uncontrolled diabetes of HbA1c>7.5
  • Neuromuscular pathology of the ipsilateral leg
  • Second-look knee arthroplasty
  • Inability to communicate (e.g. dementia)
  • Hypersensitivity to ropivacaine
  • BMI > 40
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Single shot adductor canal block

    Procedure: Single shot adductor canal block

  • Active comparator
    Continuous adductor canal block

    Procedure: Continuous adductor canal block

Interventions

  • ProcedureSingle shot adductor canal block

    Single shot adductor canal block on the the first and second postoperative day.

  • ProcedureContinuous adductor canal block

    A catheter will be placed in the adductor canal and connected to a continuous patient-controlled analgesia pump.

06

What researchers measure

Primary outcomes

  1. Average NRS pain score at rest

    average of numerical rating scale (0: no pain, 10: worst imaginable pain) pain scores from 8 time points during 48h (+4h, +8h, +12h from end of surgery, 6AM, 2PM, 10PM of postoperative day 1, and 6AM and 2PM of postoperative day 2)

    Time frame: first 48h after end of surgery

Secondary outcomes

  1. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score at rest at +4h from end of surgery

    Time frame: +4h from end of surgery

  2. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score during movement at +4h from end of surgery

    Time frame: +4h from end of surgery

  3. NRS pain score at rest at +8h from end of surgery

    Time frame: +8h from end of surgery

  4. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score during movement at +8h from end of surgery

    Time frame: +8h from end of surgery

  5. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score at rest at +12h from end of surgery

    Time frame: +12h from end of surgery

  6. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score during movement at +12h from end of surgery

    Time frame: +12h from end of surgery

  7. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score at rest at 6AM on postoperative day 1

    Time frame: 6AM on postoperative day 1

  8. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score during movement at 6AM on postoperative day 1

    Time frame: 6AM on postoperative day 1

  9. NRS pain score at rest at 2PM on postoperative day 1

    Time frame: 2PM on postoperative day 1

  10. NRS pain score during movement at 2PM on postoperative day 1

    Time frame: 2PM on postoperative day 1

  11. NRS pain score at rest at 10PM on postoperative day 1

    Time frame: 10PM on postoperative day 1

  12. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score during movement at 10PM on postoperative day 1

    Time frame: 10PM on postoperative day 1

  13. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score at rest at 6AM on postoperative day 2

    Time frame: 6AM on postoperative day 2

  14. NRS pain score during movement at 6AM on postoperative day 2

    Time frame: 6AM on postoperative day 2

  15. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score at rest at 2PM on postoperative day 2

    Time frame: 2PM on postoperative day 2

  16. numerical rating scale (0: no pain, 10: worst imaginable pain) pain score during movement at 2PM on postoperative day 2

    Time frame: 2PM on postoperative day 2

  17. Posteoperative opioid administration in morphine equivalents

    Time frame: from end of surgery to 48h after surgery

  18. Incidence of catheter tip dislocation

    The catheter tip is considered to be dislocated if the catheter tip is located outside the adductor canal

    Time frame: at 2PM on postoperative day 1 and 2

  19. Incidence of extravasation from catheter insertion site

    Time frame: at 2PM on postoperative day 1 and 2

  20. Incidence of sleep disturbance due to pain

    Time frame: from end of surgery to postoperative day 2

  21. Incidence of numbness of anterior thigh area

    Time frame: at 2PM on postoperative day 1 and 2

  22. Strengh of quadratus femoris muscle (unit: kgf)

    Time frame: at 2PM on postoperative day 1 and 2

  23. Incidence of falls during hospital stay

    Time frame: from end of surgery to 48h after surgery

  24. Postoperative range of motion of knee joint

    Time frame: at 2PM on postoperative day 1 and 2

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 03080, South Korea
08

References and documents

Publications

  • Kim H, Yoo S, Kwon S, Kim Y, Bae J, Kim YJ, Cho YJ, Kim JT, Lim YJ. Analgesic Efficacy of Repeated Daily Injections Versus Continuous Adductor Canal Block After Total Knee Arthroplasty: An Open-Label, Randomized Clinical Trial. Anesth Analg. 2026 Jan 1;142(1):132-139. doi: 10.1213/ANE.0000000000007427. Epub 2025 Feb 18. PubMed 39964911 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Oct 2023, 8 months.

Of 1,888 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 8 months is below that.

Counting every sponsor, half of 1,901 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Feb 14, 2023
StartActual
Feb 21, 2023
Primary completionActual
Oct 27, 2023
CompletionActual
Mar 8, 2024
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05727137
Lead sponsor
Seoul National University Hospital
Collaborators
Seoul National University
Responsible party
Seokha Yoo (Clinical assistant professor, Seoul National University Hospital) — Principal investigator
First posted
Feb 14, 2023
Start date
Feb 21, 2023
Primary completion
Oct 27, 2023
Completion
Mar 8, 2024
Last update
Apr 12, 2024

Study contacts

Seokha Yoo, MD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pain, Postoperative →

Other studies from this sponsor

Seoul National University Hospital →

Start the discussion